[1] |
中华医学会心电生理和起搏分会, 中华医师协会心律学专业委员会, 中国房颤中心联盟心房颤动防治专家工作委员会. 心房颤动:目前的认识和治疗建议(2021)[J]. 中华心律失常学杂志, 2021, 26(1): 15-88.
|
[2] |
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the society of thoracic surgeons[J]. Circulation, 2019, 140(2):125-151.
doi: 10.1161/CIR.0000000000000665
pmid: 30686041
|
[3] |
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[J]. Eur Heart J, 2021, 42(5):373-498.
doi: 10.1093/eurheartj/ehaa612
pmid: 32860505
|
[4] |
Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation[J]. Europace, 2018, 20(1):1-160.
doi: 10.1093/europace/eux274
pmid: 29016840
|
[5] |
Fortuni F, Casula M, Aanzo A, et al. Meta-analysis comparing cryoballoon versus radiofrequency as first ablation procedure for atrial fibrillation[J]. Am J Cardiol, 2020, 125(8):1170-1179.
doi: S0002-9149(20)30057-6
pmid: 32087997
|
[6] |
Calkins H, Willems S, Gerstenfeld EP, et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation[J]. N Engl J Med, 2017, 376(17):1627-1636.
doi: 10.1056/NEJMoa1701005
URL
|
[7] |
Kimura T, Kashimura S, Nishiyama T, et al. Asymptomatic cerebral infarction during catheter ablation for atrial fibrillation: Comparing uninterrupted rivaroxaban and warfarin (ASCERTAIN)[J]. JACC Clin Electrophysiol, 2018, 4(12):1598-1609.
doi: S2405-500X(18)30661-3
pmid: 30573125
|
[8] |
Kuwahara T, Abe M, Yamaki M, et al. Apixaban versus warfarin for the prevention of periprocedural cerebral thromboembolism in atrial fibrillation ablation: Multicenter prospective randomized study[J]. J Cardiovasc Electrophysiol, 2016, 27(5):549-554.
doi: 10.1111/jce.12928
URL
|
[9] |
Reynolds MR, Allison JS, Natale A, et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: The AEIOU trial[J]. JACC Clin Electrophysiol, 2018, 4(5):580-588.
doi: S2405-500X(17)31089-7
pmid: 29798783
|
[10] |
Yoshimura A, Iriki Y, Ichiki H, et al. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation[J]. J Cardiol, 2017, 69(1):228-235.
doi: S0914-5087(16)30041-7
pmid: 27131792
|
[11] |
Di Biase L, Lakkireddy D, Trivedi C, et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study[J]. Heart Rhythm, 2015, 12(6):1162-1168.
doi: 10.1016/j.hrthm.2015.02.028
pmid: 25728754
|
[12] |
Maddox W, Kay GN, Yamada T, et al. Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation[J]. J Cardiovasc Electrophysiol (2013), 24(8), 861-865.
doi: 10.1111/jce.12143
URL
|
[13] |
Nagao T, Higo S, Suzuki H, et al. Prospective comparison of periprocedural coagulation markers among uninterrupted anticoagulants for atrial fibrillation ablation[J]. Heart Rhythm, 2020, 17(3): 391-397.
doi: S1547-5271(19)30921-X
pmid: 31606462
|
[14] |
Nagao T, Inden Y, Yanagisawa S, et al. Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation[J]. Heart Rhythm, 2015, 12(9):1972-1978.
doi: 10.1016/j.hrthm.2015.04.016
pmid: 25881495
|
[15] |
Shah RR, Pillai A, Schafer P, et al. Safety and efficacy of uninterrupted apixaban therapy versus warfarin during atrial fibrillation ablation[J]. Am J Cardiol, 2017, 120(3):404-407.
doi: S0002-9149(17)30777-4
pmid: 28595862
|
[16] |
Silva MA, Futuro GMC, Mercon ES, et al. Safety of catheter ablation of atrial fibrillation under uninterrupted rivaroxaban use[J]. Arq Bras Cardiol, 2020, 114(3):435-442.
doi: S0066-782X2020000300435
pmid: 32049156
|
[17] |
Tao S, Otomo K, Ono Y, et al. Efficacy and safety of uninterrupted rivaroxaban taken preoperatively for radiofrequency catheter ablation of atrial fibrillation compared to uninterrupted warfarin[J]. J Interv Card Electrophysiol, 2017, 48(2):167-175.
doi: 10.1007/s10840-016-0214-6
pmid: 27943112
|
[18] |
Yanagisawa S, Inden Y, Ohguchi S, et al. Periprocedural management of cardiac tamponade during catheter ablation for af under uninterrupted DOAC and warfarin[J]. JACC Clin Electrophysiol, 2020, 6(7):786-795.
doi: S2405-500X(20)30155-9
pmid: 32703560
|
[19] |
Liu XH, Gao XF, Chen CF, et al. Thromboembolism and bleeding risk in atrial fibrillation ablation with uninterrupted anticoagulation between new oral anticoagulants and vitamin K antagonists: Insights from an updated meta-analysis[J]. J Thromb Thrombolysis, 2020, 50(1): 201-210.
doi: 10.1007/s11239-019-01989-5
URL
|
[20] |
Deshmukh A, Patel NJ, Pant S, et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures[J]. Circulation, 2013, 128(19):2104-2112.
doi: 10.1161/CIRCULATIONAHA.113.003862
pmid: 24061087
|